- Home
- IGMS vs QRHC Comparison
IGMS vs QRHC Comparison
Compare IGMS & QRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- QRHC
- Stock Information
- Founded
- IGMS 1993
- QRHC N/A
- Country
- IGMS United States
- QRHC United States
- Employees
- IGMS N/A
- QRHC N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- QRHC Environmental Services
- Sector
- IGMS Health Care
- QRHC Utilities
- Exchange
- IGMS Nasdaq
- QRHC Nasdaq
- Market Cap
- IGMS 82.1M
- QRHC 92.0M
- IPO Year
- IGMS 2019
- QRHC N/A
- Fundamental
- Price
- IGMS $1.13
- QRHC $2.42
- Analyst Decision
- IGMS Hold
- QRHC Strong Buy
- Analyst Count
- IGMS 8
- QRHC 2
- Target Price
- IGMS $6.14
- QRHC $12.75
- AVG Volume (30 Days)
- IGMS 155.8K
- QRHC 78.4K
- Earning Date
- IGMS 05-20-2025
- QRHC 05-12-2025
- Dividend Yield
- IGMS N/A
- QRHC N/A
- EPS Growth
- IGMS N/A
- QRHC N/A
- EPS
- IGMS N/A
- QRHC N/A
- Revenue
- IGMS $2,679,000.00
- QRHC $288,532,000.00
- Revenue This Year
- IGMS $121.76
- QRHC $7.55
- Revenue Next Year
- IGMS $46.83
- QRHC $7.03
- P/E Ratio
- IGMS N/A
- QRHC N/A
- Revenue Growth
- IGMS 25.77
- QRHC 0.05
- 52 Week Low
- IGMS $0.92
- QRHC $1.91
- 52 Week High
- IGMS $22.50
- QRHC $10.51
- Technical
- Relative Strength Index (RSI)
- IGMS 39.53
- QRHC 45.56
- Support Level
- IGMS $1.11
- QRHC $2.14
- Resistance Level
- IGMS $1.40
- QRHC $2.51
- Average True Range (ATR)
- IGMS 0.11
- QRHC 0.21
- MACD
- IGMS -0.01
- QRHC 0.07
- Stochastic Oscillator
- IGMS 5.56
- QRHC 56.60
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About QRHC Quest Resource Holding Corporation
Quest Resource Holding Corp is a national provider of waste and recycling services to customers from across multiple industry sectors that are typically larger, multi-location businesses. The company creates customer-specific programs and perform the related services for the collection, processing, recycling, disposal, and tracking of waste streams and recyclables. The company's services focus on the waste streams and recyclables from box, grocers, and other specialty retailers; automotive after-market operations such as automotive maintenance, quick lube, dealerships, and collision repair; transportation, logistics, and fleet operators; manufacturing and industrial facilities; multi-family and commercial properties; restaurant chains and food operations.